News & Updates

Show Multimedia Only

VISTAS: Volixibat alleviates cholestatic itch in PSC

16 Jun 2026 by

The investigational ileal bile acid transporter (IBAT) inhibitor volixibat provides rapid and sustained improvement in pruritus in patients with primary sclerosing cholangitis, according to the topline results of the VISTAS study.

VISTAS: Volixibat alleviates cholestatic itch in PSC

16 Jun 2026

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

15 Jun 2026 by

Patients with decompensated alcohol-related cirrhosis who abstained from alcoholic drinking achieve recompensation, which is associated with survival benefits when abstinence is sustained, reveals a study.

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

15 Jun 2026

Coeliac disease linked to increased risk of solid organ transplantation

14 Jun 2026

Individuals with coeliac disease have about a threefold increased likelihood of solid organ transplantation, according to a study.

Coeliac disease linked to increased risk of solid organ transplantation

14 Jun 2026

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026 by

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

12 Jun 2026

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

10 Jun 2026

Dupilumab has been shown to reduce symptomatic, endoscopic, and histological eosinophilic esophagitis (EoE) markers for patients treated in routine practice, as shown in the retrospective DUPEOETALY study.

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

10 Jun 2026

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

10 Jun 2026 by

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

10 Jun 2026

Heavy alcohol consumption raises CRC risk

10 Jun 2026 by

Individuals with high alcohol consumption are at increased risk of colorectal cancer (CRC), reports a study, which shows that alcohol intake may trigger colorectal carcinogenesis through mechanisms operating across major molecular pathways for CRC.

Heavy alcohol consumption raises CRC risk

10 Jun 2026

LNF-based regimens may alter trajectory of CHD treatment

10 Jun 2026 by

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

LNF-based regimens may alter trajectory of CHD treatment

10 Jun 2026

Daraxonrasib makes history in one of the deadliest cancers

09 Jun 2026 by

Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

Daraxonrasib makes history in one of the deadliest cancers

09 Jun 2026

First-in-class P-CAB a game-changer in H. pylori eradication

09 Jun 2026 by

Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), produces a sustained gastric acid suppression effect that is both more profound and more rapid than that of proton pump inhibitors (PPIs), making it an essential component of first-line (1L) and second-line (2L) therapy for Helicobacter pylori eradication, according to Professor Takashi Kawai of Tokyo Medical University Hospital, Tokyo, Japan.

First-in-class P-CAB a game-changer in H. pylori eradication

09 Jun 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

VISTAS: Volixibat alleviates cholestatic itch in PSC

VISTAS: Volixibat alleviates cholestatic itch in PSC

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

Alcohol abstinence enables recompensation, prolongs survival in cirrhosis

Coeliac disease linked to increased risk of solid organ transplantation

Coeliac disease linked to increased risk of solid organ transplantation

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

EMERALD-3: Unresectable liver cancer gets PFS benefit with treatment combination strategies

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

Heavy alcohol consumption raises CRC risk

Heavy alcohol consumption raises CRC risk

LNF-based regimens may alter trajectory of CHD treatment

LNF-based regimens may alter trajectory of CHD treatment

Daraxonrasib makes history in one of the deadliest cancers

Daraxonrasib makes history in one of the deadliest cancers

First-in-class P-CAB a game-changer in H. pylori eradication

First-in-class P-CAB a game-changer in H. pylori eradication